SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is in the spotlight as investors react to a record revenue report and raised full-year guidance, with the community actively debating whether the earnings reaction is a short-term shakeout or a sign of long-term growth. The high short interest has fueled significant discussion around the potential for a short squeeze as shareholders weigh the company's aggressive investment phase and expanding drone technology backlog against the EPS miss.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is experiencing significant volatility as investors debate the impact of delayed mission timelines against a massive, rapidly expanding backlog. The community remains sharply divided, with some traders viewing the current price as a deep-value buying opportunity while others express skepticism regarding execution, potential dilution, and persistent earnings misses.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending following the delivery of its Horizon 1 AI data center to Microsoft and the achievement of NVIDIA Exemplar Cloud status, fueling strong investor optimism. The community is actively debating the stock's potential for a short squeeze, citing high institutional ownership and substantial short interest as key drivers for a potential run toward the $50 level.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco Systems is currently trading in the spotlight as investors digest recent double-beat quarterly results and updated long-term guidance driven by a "networking supercycle." While shares experienced significant volatility following the report, the community remains actively divided between those betting on long-term AI infrastructure growth and those concerned that the stock's recent rally left little room for immediate upside.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending as investors digest the impact of the DaVita contract, which is being viewed as a significant operational milestone for the long-term adoption of DefenCath. While sentiment remains strongly bullish due to the contract news and recent financial updates, message boards are actively debating the company's future guidance and the ongoing influence of institutional positioning versus retail sentiment.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors focus on the company's progress toward a Q4 2026 BLA submission for its prostate cancer therapy, alongside optimism surrounding its upcoming presentation at the August Canaccord Genuity Growth Conference. The community is actively debating the significance of recent institutional accumulation and manufacturing milestones, while weighing the potential impact of competitive oncology developments on the company's valuation.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies is trending as investors digest strong sector read-throughs from peers and a price target raise from Goldman Sachs, which highlights robust artificial intelligence server demand. The community is actively debating the company's valuation metrics and backlog health, with bulls pointing to fundamental AI infrastructure growth while some traders remain cautious about recent price volatility.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is currently a focal point for investors as the community anticipates major technical updates and potential government contract announcements following a recent earnings report. Shareholders are actively debating the company's valuation compared to sector peers and expressing strong conviction in its long-term potential, despite concerns from some over market volatility and short-term price fluctuations.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras Systems is experiencing significant market volatility as investors weigh the company's recent earnings results against aggressive long-term revenue growth guidance and the impending impact of share lockup expirations. While some community members are capitalizing on the rapid price swings, others remain skeptical about the firm's valuation, leading to an active debate between those betting on long-term institutional adoption and those expecting further downside pressure.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is seeing extremely high social volume and bullish sentiment as traders focus on a potential short squeeze, fueled by a strong Q2 earnings beat and anticipation of a price-to-sales valuation re-rating. While many community members are celebrating the company's profitability and pipeline, some voices urge caution, noting that the crowd's enthusiasm and volatility may be outstripping the underlying news.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SLS It&#39;s to be expected with increasing share price before REGAL FA readout and SLS-009 catalysts, but it&#39;s real shame there are these traders throwing price targets like this. 
 
Do whatever you want with your trades but don&#39;t make comments like this throwing out $6/$7 targets. 
 
There are 99.99% chances of REGAL success, and you can read through all the DD that provides this statistically accurate prediction.  Failure is a statistical impossibility. 
 
And if you&#39;ve looked at the DD and don&#39;t understand that, you&#39;re intentionally being ignorant, ignoring what is clear as day. 
 
Real upside from $5.50 a share is 5X to 29X.  I encourage everyone to hold through REGAL FA and buyout, as the strategic acquisition will be gigantic. 
 
Do whatever you want with your trades but don&#39;t try to downplay the upside.  And stop comparing SLS to any other biotech, it&#39;s an ignorant comparison.  This isn&#39;t &quot;binary,&quot; it&#39;s deep value given the margin of safety in the trial. 
 
Fortunes will be made with sizeable positions.

Slippin Jimmy RETURNS

Enrico Papke

Geukinas

🤠

YEHMINGZHU

Louise

Dr. Arogart

Federico

Mark Hansen

Stocktwits

Ehrenhardt

Emagen

Paulstoxk

Bennyterner

Duncan Teo

Alan

Webbie

Easy E

Dave

Paul Fields

Khari Knapp

F. S. Fetchet

mrittika1971

Spaceyboy

Chessdoc

John

johnychicago

Patrick

$SLS  For those that didn&#39;t realize, my question was sincere as I&#39;ve been a strong supporter of $SLS for over 2 years.  Bullish on every post...and get attacked for asking a simple question.   
 
Thanks for those that were cordial and shared their DD (regardless of side, they are all data points so thank you). 
 
For the $SLS &quot;can&#39;t miss&quot; bro pumpers, take a lesson from $ALT.   
 
For the $ALT low life&#39;s attacking any post I make because I exposed $ALT, thanks to continue to show I live rent free in your head.  
 
My first $SLS post - March 1, 2024...Bullish

StockTwits Web

SELLAS Life Sciences Group Inc

Altimmune Inc

The Legendary Mayor

 It's to be expected with increasing share price before REGAL FA readout and SLS-009 catalysts, but it's real shame there are these traders throwing price targets like this. 
 
Do whatever you want with your trades but don't make comments like this throwing out $6/$7 targets. 
 
There are 99.99% chances of REGAL success, and you can read through all the DD that provides this statistically accurate prediction.  Failure is a statistical impossibility. 
 
And if you've looked at the DD and don't understand that, you're intentionally being ignorant, ignoring what is clear as day. 
 
Real upside from $5.50 a share is 5X to 29X.  I encourage everyone to hold through REGAL FA and buyout, as the strategic acquisition will be gigantic. 
 
Do whatever you want with your trades but don't try to downplay the upside.  And stop comparing SLS to any other biotech, it's an ignorant comparison.  This isn't "binary," it's deep value given the margin of safety in the trial. 
 
Fortunes will be made with sizeable positions.

@yG19 most here know this penny flip, flips and flops like fish washed up and in with the shore….

Herda Christian

Roger Rabbit $5,56

Robert

 most here know this penny flip, flips and flops like fish washed up and in with the shore….

5,500% ROI this quarter

@yG19 BioRich is strange... almost pathological, if you read through all his posts. How can he waste his time badmouthing something like ALT!? He probably just wants attention to promote VERU! Good luck with that!

 BioRich is strange... almost pathological, if you read through all his posts. How can he waste his time badmouthing something like ALT!? He probably just wants attention to promote VERU! Good luck with that!

@yG19 Greetings.  I think you misread my post.  It was from 2 years ago and referenced the analyst PTs.  As you&#39;ll see on that post, $SLS was under a buck.  No PTs made then and no PTs made now.   
 
As for the 99.99% chance and your eager optimism, it&#39;s a flag.  Caused me to look.  You are posting solely to $SLS and have no Watchlist.  Not sure how good you are, but that&#39;s a flag as well.  Combined, they are a red flag.  
 
As for comparison to other bios, I was only referring the scammish vibe that was felt on the ALT board.  That&#39;s all.  Not even the same sectors.  But, unfortunately, your post supports the scammish vibe on $SLS.

Paul Nipkow

 Greetings.  I think you misread my post.  It was from 2 years ago and referenced the analyst PTs.  As you'll see on that post, 

 was under a buck.  No PTs made then and no PTs made now.   
 
As for the 99.99% chance and your eager optimism, it's a flag.  Caused me to look.  You are posting solely to 

 and have no Watchlist.  Not sure how good you are, but that's a flag as well.  Combined, they are a red flag.  
 
As for comparison to other bios, I was only referring the scammish vibe that was felt on the ALT board.  That's all.  Not even the same sectors.  But, unfortunately, your post supports the scammish vibe on 

@yG19 mute this guy… he is a hired hack for shorts.  He blindly bashes with no DD.
Don’t waste an ounce of energy or thought to this guy
He is a looser

StockTwits for iOS

 mute this guy… he is a hired hack for shorts.  He blindly bashes with no DD.
Don’t waste an ounce of energy or thought to this guy
He is a looser

Ricko4

@yG19 IG19, excellent DD as always. I’ve had @Biorich blocked for ages because he’s a toxic joke, so I’m replying here in your thread. 🚫
It’s pathetic how this &#39;Dean&#39; copy-pasted your hard work and 99.9% stats just to act smart while calling $ALT investors &#39;low lives.&#39; Anyone with a brain knows Pemvidutide is a masterpiece molecule for liver health and muscle mass—something his parrot-brain clearly can&#39;t grasp. He’s a hypocritical gasbag who does zero original research and lives off your credit. Absolute loser. Real investors see right through his &#39;national sport&#39; of bashing value. Keep up the great work, IG

 IG19, excellent DD as always. I’ve had 

 blocked for ages because he’s a toxic joke, so I’m replying here in your thread. 🚫
It’s pathetic how this 'Dean' copy-pasted your hard work and 99.9% stats just to act smart while calling 

 investors 'low lives.' Anyone with a brain knows Pemvidutide is a masterpiece molecule for liver health and muscle mass—something his parrot-brain clearly can't grasp. He’s a hypocritical gasbag who does zero original research and lives off your credit. Absolute loser. Real investors see right through his 'national sport' of bashing value. Keep up the great work, IG